Polyethylenimine-based micro/nanoparticles as vaccine adjuvants [Corrigendum]

Polyethylenimine-based micro/nanoparticles as vaccine adjuvants [Corrigendum]

[This corrects the article on p. 5443 in vol. 12, PMID: 28814862.].

Polyethylenimine-based micro/nanoparticles as vaccine adjuvants

Vaccines have shown great success in treating and preventing tumors and infections, while adjuvants are always demanded to ensure potent immune responses. Polyethylenimine (PEI), as one of the well-studied cationic polymers, has been used as a transfection reagent for decades. However, increasing evidence has shown that PEI-based particles are also capable of acting as adjuvants. In this paper,...

Chemokines as Cancer Vaccine Adjuvants

We are witnessing a new era of immune-mediated cancer therapies and vaccine development. As the field of cancer vaccines advances into clinical trials, overcoming low immunogenicity is a limiting step in achieving full success of this therapeutic approach. Recent discoveries in the many biological roles of chemokines in tumor immunology allow their exploitation in enhancing recruitment of antig...

Adjuvants in Primates CpG Oligodeoxynucleotides as Vaccine

CpG oligodeoxynucleotides as vaccine adjuvants in primates.

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants in mice, boosting the humoral and cellular response to coadministered Ags. CpG ODN that stimulate human PBMC are only weakly active in mice. Thus, alternative animal models are needed to monitor the activity and safety of "human" CpG ODN in vivo. This work demonstrates that rhesus macaques recognize...